Heparin Crisis Spurs Changes In FDA Emergency Response Policies
This article was originally published in The Tan Sheet
Executive Summary
Internal and external evaluations of FDA's handling of the heparin contamination crisis of early 2008 have led to changes in the agency's emergency response strategy and a new policy on emergency collaborations with outside experts.
You may also be interested in...
Barton Attracts Support In Uphill Bid For Energy and Commerce Chair
Rep. Joe Barton pushes to regain the Energy and Commerce Committee chair against the long odds of fellow Republicans appointing him to the post that wields significant influence over FDA and the OTC drug and nutritional product industries.
Heparin Fallout Likely To Impact Supplement Ingredient Testing Exemptions
The discovery of adulterated ingredients in imported prescription drugs will likely cause increased scrutiny of supply chain operations for other segments across the food and drug industries
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.